TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (“Solasia”), a private oncology specialized pharmaceutical company developing oncology products for Asian commercial markets, announced today the filing of a New Medical Device Application for episil® (SP-03) in Japan and China.
episil® oral liquid represents a unique and innovative concept for local treatment of pain associated with oral mucositis (OM). Developed using the award-winning* Camurus proprietary technology FluidCrystal®, episil® is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms to a strongly bioadhesive film that mechanically protects the sensitized and sore mucosa of the oral cavity. Clinically demonstrated, episil® has been shown to rapidly (within minutes) and effectively reduce oral pain for up to 8 hours. episil® oral liquid is the only product for OM that is supplied as a ready-to-use, pocket-sized device helping patients maintain their quality of life while undergoing cancer therapy. episil® was first launched in Europe in 2009 and is today commercially available in a number of countries, including the U.S. where it was launched by key global pharmaceutical players. episil® oral liquid is a medical device class 1 in Europe and a 510(k) registered medical device in the U.S.
Solasia acquired exclusive commercialization rights in Japan and China to episil® from Camurus and had been developing since.
*FluidCrystal® was awarded the “Best innovation in formulation” prize at the CPhI Worldwide in 2013
Solasia was formed in November 2006 by MPM Capital and ITOCHU Corporation to address unmet needs for important new Western oncology therapies and supportive care products throughout Asia. The company’s mission is to expedite patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. Solasia completed Series D financing of JPY2.08 billion in August 2015. The funds will be used to prepare for launch of Sancuso® and further advance clinical development of its existing pipeline. To date, Solasia has raised approximately $80 million in venture financing. Additional information is available at http://www.solasia.co.jp/en/.